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Identification of a non-canonical E-box motif as a regulatory element in the
proximal promoter region of the apolipoprotein E gene
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We have used the yeast one-hybrid system to identify tran-
scription factors with binding capability to specific sequences in
proximal regions of the apolipoprotein E gene (APOE ) promoter.
The sequence between fi113 and fi80 nt, which contains regu-
latory elements in various cell types, was used as a bait to screen
a human brain cDNA library. Four cDNA clones that encoded
portions of the human upstream-stimulatory-factor (USF) tran-
scription factor were isolated. Electrophoretic-mobility-shift
assays (‘EMSAs’) using nuclear extracts from various human
cell lines as well as from rat brain and liver revealed the formation
of two DNA–protein complexes within the sequence CACCT-
CGTGAC (region fi101}fi91 of the APOE promoter) that
show similarity to the E-box element. The retarded complexes
contained USF1, as deduced from competition and supershift
assays. Functional experiments using different APOE promoter–
luciferase reporter constructs transiently transfected into U87,
INTRODUCTION
Apolipoprotein E (ApoE) has a key role in the metabolism of
plasma lipoproteins by serving as a ligand for the low-density-
lipoprotein-receptor family [1]. ApoE is a single-chain poly-
peptide of 299 amino acids in which the presence of either
arginine or cysteine at amino acid position 112 and 158 [2]
defines three human ApoE variants : E2, E3 and E4 [3,4]. A
number of previous in itro and in io studies, as well as recent
experiments with ApoE-deficient mice and human ApoE-gene
(APOE ) transgenic mice, reveal that ApoE plays an important
role in neuronal maintenance and repair [5–8]. Genetic studies
have demonstrated that ApoE4 is an important risk factor for
late-onset Alzheimer’s disease [9,10]. This allele is also responsible
for poor outcome after brain injury [11,12], stroke [13] or
neurotoxic damage [8].
Although the major site of synthesis is the liver, the protein is
also produced in extrahepatic tissues, such as the adrenals and
the nervous system. In the human brain, astrocytes are the major
site of immunoreactive ApoE [14], particularly the Bergmann
glia of the cerebellum, but it is also found in subpopulations of
neurons in the cortex and the hippocampus [15]. Several studies
have demonstrated changes in astrocyte ApoE production in
response to neurodegenerative insults in the hippocampus [16],
or in response to inflammatory mediators [17] ; however, the
regulation of this gene remains largely unexplored in the brain,
in spite of its importance in process of degeneration and
regeneration of the nervous system. Previous studies demon-
strated that transcriptional regulation of the human APOE gene
is influenced by multiple regulatory elements in its promoter.
Abbreviations used: AD, Alzheimer’s disease ; ApoE, apolipoprotein E; APOE, human apolipoprotein E gene; bHLH, basic helix–loop–helix ; DN-USF,
dominant-negative form of USF1; EMSA, electrophoretic-mobility-shift assay ; His-USF1, histidine-tagged USF1 protein ; TFE, transcription factor E ;
URE, upstream regulatory element ; USF, upstream stimulatory factor.
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HepG2 or HeLa cell lines showed that mutations that precluded
the formation of complexes decreased the basal activity of the
promoter by about 50%. Overexpression of USF1 in U87
glioblastoma cells led to an increased activity of the promoter
that was partially mediated by the atypical E-box. The stimu-
latory effect of USF1 was cell-type specific, as it was not observed
in hepatoma HepG2 cells. Similarly, overexpression of a USF1
dominant-negative mutant decreased the basal activity of the
promoter in glioblastoma, but not in hepatoma, cells. These data
indicated that USF, and probably other related transcription
factors, might be involved in the basal transcriptional machinery
of APOE by binding to a non-canonical E-box motif within the
proximal promoter.
Key words: Alzheimer’s disease, apolipoprotein E, E-box, gene
regulation, nervous system, upstream regulatory factor (USF).
Regulatory elements were identified at nucleotides fi193 to
fi124 upstream of the first exon [named region URE1 (upstream
regulatory element 1)], at nucleotides fi366 to fi246 (URE2)
and a functional GC box at fi59 to fi45 [18,19]. In addition, a
DNase I footprint was identified at fi103 to fi87 (named
URE3) [18–20] by using nuclear extracts from various cell lines.
However, the nature of the transcription factors that bind to
these regions is poorly defined.
The importance of the regulatory region of the APOE gene in
the production of ApoE in the brain is emphasized by the recent
identification of a number of polymorphisms within the promoter
[21,22]. Because some of these polymorphic sites are associated
with increased risk of Alzheimer’s disease [23,24], we have
investigated the regulatory elements that specify its expression in
neural cells. Previously we identified the transcription factor AP-2
as a mediator of the cAMP stimulation of ApoE synthesis in
glial cells [25] ; moreover, we have shown that transcription
factors Zic1 and Zic2 bind and transactivate the apolipoprotein
E gene promoter in glioblastoma cells [26].
Upstream stimulatory factor (USF) is a ubiquitous tran-
scription factor that belongs to the class B proteins of the basic
helix–loop–helix (bHLH) family. It also contains a leucine zipper
that contributes to dimerization of the protein. USF was first
identified as a stimulator of transcription from the adenovirus
late promoter [27] and was purified as two polypeptides of 43 and
44 kDa termed USF1 and USF2 [28]. USF1 and USF2 bind to
the E-box motif (CACGTG) as mono- and hetero-dimers [29].
Other transcription factors, including Myc, Max, transcription
factor E3 (TFE3), TFEB, TFEC, as well as transcriptional
repressors of the Mad family and Mnt, bind to the E-box motif.
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The E-box motif is present in a large number of genes; however,
how a given response element can discriminate among all these
different transcription factors is currently unclear. In this respect,
several mechanisms have been proposed and, in some instances,
experimentally substantiated (for a review, see [30]). For instance,
deviations from the consensus sequence found in non-canonical
sites might allow preferential binding of a subset of complexes.
Also the flanking sequences, chromatin structure, methylation
status, relative position within the promoter or interaction with
adjacent regulatory elements might contribute to selection of a
particular complex [30]. USF has been involved in the basal
transcription of a number of genes, including genes for rat
c-fibrinogen [31], murine metallothionein I [32], human CD2
[33], human b-globin [34] and rat amyloid b-protein precursor
[35], among others. USF also plays a role in the signal-induced
regulation of the l-pyruvate kinase gene [36] or the fatty acid
synthase [37].
In the present study we searched for transcription factors with
binding capability to the fi113 to fi80 sequence of the APOE
gene, a region that contains the above-mentioned regulatory
element URE3 [18–20,37,38]. We have localized a functional
E-box-like element within this region, and identified transcription
factor USF1 as a transcriptional activator for APOE gene in the
astroglial cell line U87.
EXPERIMENTAL
Reporter constructs for library screen
The oligonucleotides TCGGGAGAACAGCCCACCTCGTG-
ACTGGGGGCTGGC and CCGAGCCAGCCCCCAGTCA-
CGAGGTGGGCTGTTCTC, containing the URE3 region
[18–20] of the APOE promoter, were synthesized and annealed.
The annealed oligonucleotide displayed overhanging ends
(underlined) to promote oriented oligomerization upon ligation
in the plasmid pAEA [39]. A fragment containing five tandem
repeats was subcloned into the yeast reporter plasmids, pHIS-1
and pLacZi (Clontech, Palo Alto, CA, U.S.A.), yielding plasmids
APOE3-pHIS-1 and APOE3-pLacZi respectively. The reporter
constructs were subsequently linearized and sequentially
integrated into the genome of the yeast strain YM4271. Yeast
was transformed first with APOE3-pLacZi, followed by APOE3-
pHIS-1. Transformants selected on Leu−}Ura− minimal medium
(i.e. lacking leucine and uracil) were used as a dual reporter host
yeast strain for the library screening.
Screening of the cDNA library
The host yeast strain was transformed with a MATCHMAKER
human brain cDNA library constructed in the pGAD10 vector
(Clontech) by the lithium acetate}poly(ethylene glycol) method
(http:}}www.clontech.com}techinfo}manuals}PDF}PT3024-1.
pdf). Approx. 5‹10% transformants were plated per 150-mm-
diameter dish containing His−}Leu− minimal selective medium
supplemented with 15 mM 3-aminotriazole. Approx. 2.5‹10’
cDNA plasmids were screened. On the basis of large colony size
and rapid growth, a total of eight positive clones were selected.
These clones were tested for b-galactosidase activities using the
filter replica method. Four clones showed a strong blue colour
compared with the host strain. Plasmids were recovered from
His+}LacZ+ colonies by transformation into DH5a cells. The
plasmids were partially sequenced and the nucleotide sequences
were compared with sequences in the GenBank2}EMBL data-
bases using the BLAST program.
Purification of recombinant histidine-tagged USF1 protein
(His-USF1)
To produce His-USF1 we prepared a bacterial expression con-
struct by transferring cDNA inserts from the yeast pGAD10
vector into the BamH1}BglII sites of the prokaryotic ex-
pression vector pTrcHisA (Invitrogen Inc., San Diego, CA,
U.S.A.). Expression of His-USF was induced in the Escherichia
coli strain BL21and purified with Ni#+-nitrilotriacetate resins
(Qiagen Inc, Valencia, CA, U.S.A.) using a batch protocol as
recommended by the manufacturer.
Electrophoretic-mobility-shift assay (EMSA)
Oligonucleotides were 5«-end-labelled with [c-$#P]ATP using T4
polynucleotide kinase. Recombinant His-USF1 or nuclear
extracts (0.5–1 lg) were incubated for 15 min at room tem-
perature in 20 ll of binding buffer [Tris}HCl (pH 7.6)}100 mM
NaCl}1 mM MgCl
#
}0.5 mM EDTA}1 mM dithiothreitol,
supplemented with 2 lg of poly(dI-dC) [poly(dI-dC)}assay].
Where indicated, competitor oligonucleotides were included
during the preincubation period. In supershift assays, antibodies
against USF1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
U.S.A.) were also included during the preincubation, the length
of which was extended to 40 min. Labelled oligonucleotide
(1 ng}binding reaction, 100000–200000 c.p.m.) was then added,
and the mixture was incubated for 30 min at room temperature.
The incubation mixture was electrophoresed on 4% poly-
acrylamide gels containing 0.5‹TBE (45 mMTris}borate}1 mM
EDTA) buffer. Gels were dried and autoradiographed.
Plasmid constructions
The luciferase reporter plasmid pXP2 [40] was used to harbour
different fragments of the APOE promoter. The fragments were
generated byPCR using oligonucleotides from the desired regions
as primers and the APOE-pCRII construct [25] as a template.
Amplified fragments were ligated to the pCRII vector
(Invitrogen), and the identity was confirmed by sequencing.
Fragments were subcloned in the MCS of pXP2 in front of the
luciferase reporter gene. Mutations were introduced by PCR by
using mutant oligonucleotides as previously described [41]. A
dominant-negative form of USF that contained an internal
deletion of amino acids 200–212 [42] was derived from the wild-
type USF1 by PCR, the method of Higuchi [41] being followed.
Cell culture and transfections
U87, HepG2 or HeLa cells were grown in Dulbecco’s modified
Eagle’s medium containing 10% (v}v) fetal-bovine serum. Trans-
fections were performed with 0.5 lg of DNA per well in 24-well
tissue-culture plates by using the CalPhosTM Mammalian Trans-
fection kit (Clontech) according to the instructions of the
manufacturer.
Luciferase and b-galactosidase assays
Cells were harvested on day 2 following transfection with 150 ll
of a lysis buffer containing 25 mM Tris}phosphate, 2 mM
dithiothreitol, 2 mM EDTA, 10% (v}v) glycerol, 1% Triton
X100. Luciferase was measured using the Luciferase Assay
System (Promega, Madison, WI, U.S.A.) in a Monolight 2010
luminometer (Analytical Luminescence Laboratory, San Diego,
CA, U.S.A.) by incubation of 40 ll of cell extract with 90 ll of
luciferase assay reagent as recommended by the manufacturer.
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b-Galactosidase was determined in a 96-well microtitre plate
by incubating 20 ll of cellular extract with 20 ll of a solution
containing 3 mg}ml o-nitrophenyl b-d-galactopyranoside. Rela-
tive luciferase activity was calculated as the ratio between
luciferase and b-galactosidase activities.
RESULTS
Isolation of cDNA clones encoding an APOE-promoter-binding
protein
We were interested in identifying transcriptional factors that
regulate the expression of the APOE gene. Since sequences in the
proximal regions of the APOE promoter have been demonstrated
to be functionally important for the regulation of the ApoE
expression, we attempted to clone new transcription factors
capable of binding the 5«-flanking region upstream of the TATA
box of the APOE gene (Figure 1A). In the present study we
selected the fi113}fi80 region, as deletion analyses and DNA
footprinting experiments had previously revealed the presence
of regulatory sequences and protein binding within this region of
the promoter. We employed the yeast one-hybrid assay to screen
a human brain cDNA library. Five tandem copies of the duplex
DNA containing the sequence spanning fi113 to fi80 of the
APOE promoter (region URE3) were linked to a minimal HIS3
Figure 1 Binding of recombinant His-USF to the w113/w80 ApoE
promoter sequence
(A) Diagram of the proximal APOE promoter showing the location of some putative regulatory
elements. TATA, the TATA box element ; GC, the GC box element ; URE1 and URE3 have already
been defined [18,20] ; ERE, oestrogen response element. Binding sites for transcription factors
SP1 (simian-virus-40 protein 1), AP2 (activator protein 2), ZIC (zinc finger of the cerebellum)
and BEF-1 (BK virus enhancer factor-1) are indicated. (B) The gel-mobility-shift assay was
performed with 1 ng of 32P-labelled fi113/fi80 DNA fragment incubated with 500 ng of
bacterial control extract (lane 1) or purified His-tagged USF (lane 2).
promoter either in pHIS1 or in pLacZi reporter plasmids and
integrated into the genome of the yeast strain YM4271 (his3,
leu2) (HIS3 is the reporter gene conferring prototrophy on
yeast). A hybrid expression library (MATCHMAKER) con-
sisting of human brain cDNA fused to the GAL4 activation
domain was then screened to identify proteins that bound to the
APOE promoter fragment and activated HIS3 transcription
from the reporter construct. Transformants growing on selective
medium were assayed for b-galactosidase expression. After
screening 2.5‹10’ independent colonies, eight colonies grew on
His−}Leu− selective medium. Four of them produced strong blue
colour on filter assay after 1 h of incubation in the presence of
5-bromo-4-chloroindol-3-yl b-d-galactopyranoside (‘X-Gal ’).
Plasmids of these transformants were then recovered and
sequenced. Sequence analysis revealed that all four clones
encoded to different portions of the same USF1 transcription
factor and were in-frame with the activation domain of GAL4.
The two longest clones encoded proteins missing the 34 N-
terminal amino acids.
USF1 binds to the APOE promoter
To confirm the presence of USF1-binding sites in the APOE gene
promoter, we first produced His-tagged USF1 proteins by
transferring the USF1-encoding inserts from the yeast vector
pGAD10 to the prokaryotic expression vector pTrcHisA. The
recombinant proteins were then purified on nickel-containing
resins. The binding activity of the recombinant protein was
assayed by EMSA using as a probe the radioactively labelled
oligonucleotide covering bases fi113}fi80 (Figure 1B). No
bands of retarded mobility were observed in the absence of
recombinant protein, whereas a retarded band was detected in
the presence of purified His-tagged USF1.
Next we analysed the presence of USF binding activity by
EMSA in nuclear extracts derived from diverse cell lines and
tissues, using as a probe the double-stranded bait oligonucleotide.
When labelled fi113}fi80 was incubated with HeLa nuclear
extracts, several retarded complexes were apparent (Figure 2,
lane 2). The two upper bands (complex 1}2) were competed for
by a molar excess of unlabelled double-stranded fi113}fi80 oligo-
nucleotide (lane 3), as well as by the shorter fi107}fi88
oligonucleotide (lane 4) and by an oligonucleotide containing the
consensus E-box sequence (lane 5), but not by comparable
amounts of an oligonucleotide derived from the adjacent APOE
promoter region (fi163}fi124) (Figure 2, lane 6). No dis-
placement was observed by other unrelated oligonucleotides
(results not shown). The nature of the lower bands observed with
this probe (Figure 2, arrowheads) is unclear, as they were
displaced by fi113}fi80 and fi107}fi88 oligonucleotides, but
also by the unrelated oligonucleotide fi163}fi124. These bands
were partially displaced by the USF consensus oligonucleotide.
When we used as a probe a labelled oligonucleotide containing
the E-box consensus sequence (Figure 2, lanes 7–12), we
observed the presence of two complexes with a pattern of
displacement similar to that described above: both the fi113}
fi80 and fi107}fi88 oligonucleotides displaced the binding
and, as expected, these later complexes were also displaced by a
molar excess of the unlabelled E-box oligonucleotide, but not by
the unrelated one (Figure 2, lanes 9–12).
To confirm that USF1 is a component of the observed
complexes, we performed supershift assays by incubation of
probe fi107}fi88 and USF1 antibodies with nuclear extracts
derived from HeLa cells, U87 glioblastoma cells, HepG2 hepa-
toma cells, rat brain or rat liver (Figure 3A). The two complexes
observed in the absence of antibodies for all the three extracts
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Figure 2 Interaction of nuclear extracts of HeLa cells with w107/w88 fragment of APOE promoter and with E-box consensus oligonucleotide
EMSAs were performed with 1 ng of double-stranded 32P-labelled probe (fi113/fi80 APOE DNA fragment, or E-box consensus oligonucleotide) incubated with 500 ng of HeLa nuclear extracts
in the absence (lane 2 and lane 8) or the presence of a 100 M excess of the indicated unlabelled competitor oligonucleotides. These oligonucleotides correspond to the consensus sequence for
USF binding, or to the regions fi113/fi80, fi107/fi88 and fi163/fi124 of the APOE gene promoter (lanes 3–6 and 9–12). Lanes 1 and 7 correspond to the probes in the absence of
nuclear extracts. Note that formation of Complex 1/2 was prevented by excess of oligonucleotides covering the URE3 region of APOE gene as well as by the E-box consensus oligonucleotide.
The nature of the higher-mobility bands (arrowheads) is uncertain (see the text).
(lanes 1, 3, 5, 7 and 10, complexes 1}2) disappeared and, instead,
new complexes were now evident (lanes 2, 4, 6, complex 3). The
smeared appearance of these bands probably reflects the presence
in the retarded complexes of both homo- and hetero-dimers
containing USF1 that would bind different amounts of antibody.
These supershifted complexes were not observed in the presence
of an unrelated control antibody (Figure 3A, lanes 9 and 12). The
band pattern observed with the APOE probe was identical with
that observed using the E-box consensus sequence as a probe and
nuclear extracts of HeLa, HepG2 or U87 cell lines (Figure 3B).
Within this region, the sequence −"!"CACCTCGTGAC−*"
presents a single mismatch when compared with the USF binding
sequence in the adenovirus major late promoter CACGTGAC.
Alternatively, this APOE sequence can be view as identical with
the consensus with the insertion of the nucleotides CTC between
the CAC and GTG sequences of the consensus E-box.
Delineation of nucleotide sequences required for USF binding
To determine more precisely the nucleotide sequence required for
binding of USF1 to the APOE promoter we tested the binding
ability of cerebellar nuclear extracts to a series of mutant
oligonucleotides derived from the fi107}fi88 sequence, as indi-
cated in Figure 4. Mutation of −"!"CAC−** to AAA (mutant 1,
lane 2) decreased considerably the binding of USF to the
probe. Mutation of −*)CTC−*’ to GTG did not affect the binding
(mutant 2, lane 3), probably because this mutation created a new
adjacent consensus E-box, and a mutation of this triplet
−*)CTC−*’ to TTT precluded the binding (mutant 3, lane 4).
Binding was also impaired by mutation in 3« end of this core
sequence: mutants 4 and 5 (lanes 5 and 6). Together, these results
indicate that USF binds to this atypical E-box located in the
fi101}fi91 region of the APOE promoter.
# 2003 Biochemical Society
983Upstream stimulatory factor regulates apolipoprotein E gene
Figure 3 Supershift EMSAs of USF binding
Either double-stranded 32P-labelled fi107/fi88 probe (A) or USF consensus (B) was incubated with nuclear extracts (500 ng) derived from HeLa cells, HepG2 cells, U87 cells, rat brain or rat
liver, as indicated in the Figure, in the absence or the presence of antibodies (Ab) against USF. The specific complexes formed in the absence of antibody (lanes 1, 3, 5, 7 and 10, complex 1/2)
disappeared in the presence of the antibody, and instead a supershifted smeared complex appeared (lanes 2, 4, 6, 8 and 11, complex 3). Where indicated, unrelated control antibody was included
during the incubation (lanes 9 and 12).
Role of the E-box-like element and USF1 on the APOE promoter
function
To analyse the functional role of the atypical E-box and that of
USF1 on the APOE promoter, several APOE promoter–
luciferase constructs were prepared and transiently transfected
either in U87 human astrocytoma, or in HepG2 human hepatoma
cells. Along with the test constructions, each plate was co-
transfectedwith ab-galactosidase expression vector, which served
as an internal reference for efficiency of transfection. Luciferase
and b-galactosidase activities were determined 48 h later and the
relative luciferase activity was calculated as the ratio between
luciferase and b-galactosidase activities. Mutations of the
identifiedE-box in the context of afi189}›1-luciferase construct
reduced the basal activity of the promoter by 40 and 50% in U87
and HepG2 respectively, as compared with the controls. These
results indicate a role of the atypical E-box in the regulation of
APOE in these cell types. When an expression vector for USF1
was co-transfected with different APOE constructs (Figure 5B)
we observed an increase of 5.9-fold over the control value in the
context of the fi189}›1-luciferase construct. The stimulation
was decreased to 2.7-, 2.2-, and 1.3-fold in constructs where the
E-box was absent (fi70}›1, fi60}›1 and fi40}›1-luciferase
plasmids respectively). In the construct fi189}›1m(E-box)-
Luc, where only the E-box had been eliminated, overexpression
of USF1 in U87 still increased the activity of the promoter 3.6-
fold (Figure 6A), indicating that most of the effect of the
overexpressed USF1 was independent of binding to the E-box-
like motif. These effects of USF1 were cell-type-specific, as
overexpression of USF1 in HepG2 cells did not increase the
activity of the promoter (Figure 6B).
To clarify the role of USF and that of the atypical E-box on
the activity of the APOE promoter, we used a dominant-negative
(DN) form of USF1 (DN-USF). This mutant lacking the DNA-
binding domain can dimerize with native USF and blocks its
activity [41]. Overexpression of DN-USF in U87 cells decreased
the luciferase activity of the fi189}›1-Luc construct by to 61%
of the control (black bars in Figure 6A). Instead, when the
transfection was performed with the construct mutated in
the E-box [fi189}›1m(E-box)-Luc] (white bars in Figure 6A),
the overexpression of DN-USF produced a slight increase in
luciferase activity. These results indicate that the endogenous
USF1 regulates the activity of the promoter through the E-box-
like motif. These effects were again cell-type-specific, as the DN
form of USF1 did not affect the promoter activity in HepG2 cells
(Figure 6B).
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Figure 4 Mutational analysis of USF binding to thew107/w88 region of
the APOE promoter
EMSAs were performed by incubation of 1 ng of the indicated 32P-labelled DNA fragments with
500 ng of HeLa nuclear extract. Sequences of the fi107/fi88 probe and mutations introduced
are shown. The sequence of the non-canonical E-box is underlined and shown in bold.
DISCUSSION
In the present study we have identified the sequence
CACCTCGTGAC, spanning nucleotides fi91 to fi101 of the
APOE gene, as a functional promoter element in several cell
types. This sequence is located within the formerly defined URE3
region of the promoter [34–37], and presents similarities to the
consensus E-box element CACGTG located in a number of
genes [43]. Indeed, by using the yeast one-hybrid genetic-selection
approach to screen a human brain cDNA library for sequences
encoding DNA-binding proteins that can recognize the URE3
region of the APOE gene, we isolated a human cDNA that
encodes for the transcription factor USF. EMSA studies con-
firmed the binding to the above-mentioned core sequence of USF
present in nuclear extracts derived from diverse human cell lines
as well as from rat brain and liver. Mutations within this core
sequence suppressed USF binding. USF is a member of the
bHLH family of transcription factors that binds DNA in io as
homo- or hetero-dimers of USF-1 and USF-2 to the E-box
element [43]. In addition to the consensus E-box, USF proteins
bind to other related sequences, including CGCGTG [28],
CCCGTG [27], CAGCTG [44], CACCTG [30], CACATG [33],
or CAGATG [45], all of them differing from the core CTCGTG
that we have found in the APOE promoter. Our functional data
indicate that mutations in this sequence of the APOE gene
decrease the basal activity of the promoter in all the cell types
Figure 5 Role of the E-box-like element and USF on the APOE promoter
activity
(A) U87 or HepG2 cells were transiently transfected with the wild-type fi189/›1-luciferase
construct (black bars) or with a fi189/›1-luciferase construct mutated in the E-box-like
element (95GCG93 mutated to AAA) (white bars) and a b-galactosidase expression vector.
Luciferase activity was determined 48 h later and normalized for transfection efficiency as
measured by b-galactosidase activity assay. Normalized luciferase activity is presented as a
percentage of the promoter activity of the wild-type construct. (B) U87 cells were transiently
transfected with the indicated APOE promoter-luciferase constructs, ab-galactosidase expression
vector and the empty pN3 vector (black bars) or the USF expression vector pN3-USF (white
bars). Luciferase activity was determined 48 h later and normalized to b-galactosidase activity.
For each construct the results are relative to values measured in pN3-transfected cells. Values
represent means‡S.E.M. for four separate experiments each performed in triplicate. *P ! 0.05.
assayed. However, in spite of the presence of a capacity of USF
to bind to the APOE promoter in all the nuclear extracts assayed
in the present study, our functional data indicate that the effect
of USF is cell-type-specific. Thus a DN form of USF that
dimerizes with native USF, precluding binding to DNA [41],
decreased the basal activity of the promoter in U87 astrocytoma
cells, but not in hepatoma HepG2 cells. These data suggest that,
in HepG2 cells, a transcription factor other than USF must bind
to the atypical E-box. Indeed, many other transcription factors
of the bHLH family bind to E-box-like elements, including
c-Myc, Max, TFE3, TFEB, or SREBP1 [43]. Previous studies
indicate that other proteins might bind to this region of the
promoter. Jo et al. [20] purified a 67 kDa URE3-binding protein
from human placenta with affinity for the fi101 to fi89 region.
The protein was not further characterized, but its molecular mass
is clearly higher than that of USF. This region of the promoter
is also partially overlapping the binding site for the transcriptional
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Figure 6 Effect of USF and a dominant negative mutant of USF on the
APOE promoter activity in U87 and HepG2 cells
U87 cells (A) or HepG2 cells (B) were transiently transfected with the wild-type fi189/›1-
luciferase construct (black bars) or with the E-box-mutated 189/›1 construct (white bars), a
b-galactosidase expression vector and the empty pN3 vector (pN3) or the USF expression
vector pN3-USF (pN3-USF) or the DN expression vector pN3-DN-USF (pN3-DN-USF).
Luciferase activity was determined 48 h later and normalized to b-galactosidase activity. For
each construct the results are relative to values measured in cells transfected with the wild-type
fi189/›1-luc construct and empty pN3. Values represent means‡S.E.M. for four separate
experiments each performed in triplicate. *P ! 0.05.
repressor BEF-1, a protein that binds to the fi94 to fi84
sequence in HepG2 cells that could mediate the regulation of the
APOE gene by cytokines [46].
Although USF is a ubiquitous factor, it has been involved in
the transcription of genes with tissue specificity. Thus it is
conceivable that USF could regulate the APOE gene in astro-
cytoma cells either by heterodimerizing with other glioma-
specific factors, or by being incorporated into a complex of
transcription factors including co-activators, whose stereospecific
assembly allows cell-restricted gene regulation, as has been
proposed by Qyang et al. [47]. In this context, it has recently
been shown that the glial-specific expression of ApoE is governed
by two distal enhancer sequences, named ME-1 and ME-2, that
are located 3.3 and 15 kb respectively downstream of the APOE
gene [48]. It is noteworthy that, within this enhancer, there is a
perfect consensus E-box sequence. Although the functionality of
this sequence remains to be determined, it is reminiscent of that
reported for the APOCII gene, where USF bound to the proximal
promoter interacts with a second USF bound to a distal enhancer
to promote transcription of this gene in a synergistic manner
[49].
Exogenous overexpression of USF also increases the level of
transcription from the APOE promoter in a cell-specific manner,
being observed only in U87 cells, but not in HepG2 cells.
Nevertheless, much of the effect of overexpressed USF was
independent of binding to the atypical E-box and mapped
upstream of nucleotide fi40. USF has been shown to bind to the
pyrimidine initiator sequence (‘Inr ’) in a number of genes [50].
This is a quite loose sequence that would be compatible with the
pyrimidine-rich sequence found in region fi80 to fi60 of
the APOE promoter.
ApoE plays a crucial role in many physiological processes,
including cholesterol transport in the peripheral circulation and
in the central nervous system. ApoE is also involved in the
response to neural injury, maintenance of dendritic arborizations
and neuronal remodelling in itro, as well as in Alzheimer’s
disease (AD) (see [1] for a review). The recent association of
different polymorphisms in the promoter region with AD [20,21]
strongly suggests that transcriptional regulation may play an
important role in the development of this deleterious disease [18].
Thus identification and characterization of the transcriptional
machinery involved in the regulation of ApoE may be relevant
for the development of a rational pharmacology of AD.
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